3'-DMT-dC(Ac)-Suc-CPG; 1000 Å

3'-DMT-dC(Ac)-Suc-CPG; 1000 Å is a reagent used in the solid-phase synthesis of oligonucleotides, specifically for incorporating cytosine residues. It includes a 3'-DMT protective group, N4-acetyl protection on the cytosine base, and a succinyl linker that attaches the nucleoside to controlled pore glass (CPG) with a pore size of 1000 Å. This setup is designed for the efficient and accurate synthesis of longer DNA sequences, allowing precise incorporation of cytosine while ensuring easy deprotection and release from the solid support.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Catalog

BRP-02248

Synonyms

3'-O-(4,4'-Dimethoxytrityl)-N4-acetyl-2'-deoxyacytosine-5'-Suc-CPG 1000 Å; N4-Acetyl-2'-deoxy-3'-O-DMT-cytosine-5'-Suc-CPG 1000 Å; N4-Acetyl-2'-deoxy-3'-O-dimethoxytritylcytosine-5'-Suc-CPG 1000 Å

Appearance

White to off-white powder

Storage

Store at 2-8 °C

Shipping

Room temperature.

Cleavage Conditions

Use concentrated ammonia for 90 min at 25°C or 30 min at 60°C, or 1:1 ammonia:methylamine (AMA) for 25 min at 25°C when using fast deprotecting amidites.

Deprotection Conditions

When using fast deprotection amidites (such as C-Ac; G-DMF), use concentrated ammonia at 60°C for 1h or AMA for 30 min. When using standard amidites (such as C-Bz; G-iBu), please use concentrated ammonia at 60°C for 5h.

Chemical Structure:

Reference Reading

1. Therapeutic Effects of Anthocyanins for Vision and Eye Health

Yuri Nomi, Keiko Iwasaki-Kurashige, Hitoshi Matsumoto. Molecules. 2019 Sep 11;24(18):3311. doi: 10.3390/molecules24183311.

Anthocyanin (AC) is widely used as supplement of eye health in Europe and in East Asia. In this review, I describe AC effects to clarify the mechanism is important in order to understand the effects of AC on vision health. The bioavailability of AC is quite low but, reported as intact form and many kinds of metabolite. And AC passes through the blood-aqueous fluid barrier and blood-retinal barrier. In vitro study, AC had a relaxing effect on ciliary muscle which is important to treat both myopia and glaucoma. And AC stimulate the regeneration of rhodopsin in frog rod outer segment. Furthermore, AC could inhibit the axial length and ocular length elongation in a negative lens-induced chick myopia model. In addition, we summarized clinical studies of AC intake improved dark adaptation and transient myopic shift and the improvement on retinal blood circulation in normal tension glaucoma patients.

2. Litiasic acute cholecystitis: application of Tokyo Guidelines in severity grading

Alfredo Escartín, Marta González, Pablo Muriel, Elena Cuello, Ana Pinillos, Maite Santamaría, Helena Salvador, Jorge-Juan Olsina. Cir Cir. 2021;89(1):12-21. doi: 10.24875/CIRU.19001616.

Acute calculous cholecystitis (AC) is one of the most frequent surgical emergencies in our field. Laparoscopic cholecystectomy is considered the treatment of choice, although not sufficiently widespread. To analyze the application of the Tokyo Guidelines in the management of AC and to determine the influence of the degree of severity on management and prognosis. Prospective, observational study of patients with a primary diagnosis of AC between 2010 and 2015.. Exclusion criteria: AC recurrence; AC as a secondary diagnosis; acalculous cholecystitis; concurrent biliary pathology. Severity was classified according Tokyo 2013 Guidelines. 998 patients were included: 338 (33.9%) mild AC, 567 (56.8%) moderate AC, and 93 (9.3%) severe AC. A total of 582 (58.3%) patients were operated on. Postoperative complications Dindo-Clavien grade ≥ II 12.6%: mild AC 3.6%; moderate AC 12.2%; severe AC 49.0% (p < 0.001). Overall mortality 2%: mild AC 0%; moderate AC 0.5%; severe AC 18.0% (p < 0.001). Urgent laparoscopic cholecystectomy remains the treatment of choice for mild and moderate AC. In patients with severe AC, the risks and benefits of surgery should be assessed, given the high degree of complications and associated mortality.

3. Cardiac efficacy and toxicity of aconitine: A new frontier for the ancient poison

Wei Zhou, Hong Liu, Li-Zhen Qiu, Lan-Xin Yue, Guang-Jie Zhang, Hui-Fang Deng, Yu-Hao Ni, Yue Gao. Med Res Rev. 2021 May;41(3):1798-1811. doi: 10.1002/med.21777.

Aconitine (AC) is well-known as the main toxic ingredient and active compound of Aconitum species, of which several aconites are essential herbal medicines of Traditional Chinese Medicine (TCM) and widely applied to treat diverse diseases for their excellent anti-inflammatory, analgesic, and cardiotonic effects. However, the cardiotoxicity and neurotoxicity of AC attracted a lot of attention and made it a favorite botanic poison in history. Nowadays, the narrow therapeutic window of AC limits the clinical application of AC-containing herbal medicines; overdosing on AC always induces ventricular tachyarrhythmia and heart arrest, both of which are potentially lethal. But the underlying cardiotoxic mechanisms remained chaos. Recently, beyond its cardiotoxic effects, emerging evidence shows that low doses of AC or its metabolites could generate cardioprotective effects and are necessary to aconite's clinical efficacy. Consistent with TCM's theory that even toxic substances are powerful medicines, AC thus could not be simply identified as a toxicant or a drug. To prevent cardiotoxicity while digging the unique value of AC in cardiac pharmacology, there exists a huge urge to better know the characteristic of AC being a cardiotoxic agent or a potential heart drug. Here, this article reviews the advances of AC metabolism and focuses on the latest mechanistic findings of cardiac efficacy and toxicity of this aconite alkaloid or its metabolites. We also discuss how to prevent AC-related cardiotoxicity, as well as the issues before the development of AC-based medicines that should be solved, to provide new insight into the paradoxical nature of this ancient poison.